Hand, Foot and Mouth Disease Vaccine, Its Preparation Method and Application
By developing a multivalent vaccine containing inactivated CA4, EV71, CA16, and CA10 viruses, the problem of difficulty in preventing hand-foot-mouth disease caused by multiple Coxsackieviruses in existing technologies has been solved. This has achieved broad-spectrum preventive efficacy and safety, simplified the vaccination procedure, and reduced costs.
Patent Information
- Application Number
- CN202111620464.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-27
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-12-27
AI Technical Summary
Current technologies are insufficient to effectively prevent hand-foot-mouth disease caused by various Coxsackieviruses, especially types CA16, CA10, and CA6, resulting in limited vaccination effectiveness and an inability to effectively control the outbreak and spread of HFMD.
A multivalent vaccine containing inactivated Coxsackievirus A4 (CA4), Enterovirus 71 (EV71), Coxsackievirus A16 (CA16), and Coxsackievirus A10 (CA10) was developed. The vaccine was prepared using Vero cell culture, ultrafiltration, sucrose gradient centrifugation, and formaldehyde inactivation. The vaccine was combined with aluminum adjuvant to enhance the immune effect.
It achieves broad-spectrum prevention against multiple Coxsackieviruses, has good immunogenicity and safety, simplifies the vaccination procedure, reduces costs, and shows significant cytopathic effects in in vitro experiments, ensuring the stability and safety of the vaccine.
Smart Images

Figure BDA0003437358440000061 
Figure BDA0003437358440000071 
Figure BDA0003437358440000072
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a novel Coxsackievirus A4 strain, a vaccine containing this strain for the prevention or treatment of hand-foot-mouth disease, its preparation method, and its application. Background Technology
[0002] Hand-foot-mouth disease (HFMD) is an acute infectious disease caused by various enteroviruses, and it is more common in infants and young children. The main symptoms of HFMD are rashes on the mouth, hands, and feet, and it can lead to severe complications such as meningitis, encephalitis, pulmonary edema, and circulatory failure, which can result in death.
[0003] Besides enterovirus 71 (EV71) and Coxsackievirus A16 (CA16), which are relatively common viruses that cause hand-foot-mouth disease (HFMD), other common causes include Coxsackievirus A (CA) types 2, 4, 5, 6, 10, and 24; Coxsackievirus B (CB) types 1, 2, 3, 4, and 5; enterovirus 68 (EV68); and echovirus (Echo) types 6, 25, and 30. EV71 and CA16 are the main pathogens causing HFMD outbreaks. In recent years, reports of HFMD outbreaks caused by CA10, CA24, and CA6 have gradually increased, and in some areas they have even become the main circulating serotypes.
[0004] Hand, foot, and mouth disease (HFMD) has become a serious public health problem threatening children's health and social stability. Currently, there are no effective antiviral drugs for treating HFMD. Although an approved EV71 inactivated vaccine is available, changes in the enterovirus spectrum causing HFMD and the diversity of dominant strains leading to its prevalence, coupled with the lack of cross-immune protection between strains, make it impossible to protect against infections with other types of HFMD, posing new challenges to HFMD control. Furthermore, EV71 inactivated vaccines are insufficient to control outbreaks and epidemics of HFMD caused by CA16, CA10, CA6, and CA4.
[0005] Therefore, there is an urgent need for a multi-serotype combined vaccine that can prevent hand-foot-mouth disease on a wider scale in order to cope with the outbreak and epidemic of severe HFMD. Summary of the Invention
[0006] To address the aforementioned problems, this invention screened novel viral strains with good immunogenicity that can be used to prevent, treat, or combat hand-foot-mouth disease. Based on this, vaccines or agents for the prevention or treatment of hand-foot-mouth disease were developed.
[0007] According to one aspect of the present invention, a Coxsackievirus A4 (CA4) strain is provided. This strain was deposited on December 2, 2021, at the China General Microbiological Culture Collection Center (CGMCC) (No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC NO:45051.
[0008] According to another aspect of the present invention, a vaccine for the prevention of hand-foot-mouth disease is provided, the vaccine comprising an inactivated strain of the aforementioned preserved Coxsackievirus A4 (CA4) virus.
[0009] According to some embodiments of the present invention, the vaccine further includes inactivated enterovirus 71 (EV71), inactivated Coxsackievirus A16 (CA16), inactivated Coxsackievirus A10 (CA10), and / or inactivated Coxsackievirus A6 (CA6). According to some embodiments of the present invention, the vaccine includes inactivated CA4, EV71, CA16, CA10, and CA6.
[0010] According to some embodiments of the present invention, the enterovirus 71 (EV71) strain is deposited under CGMCC No. 3544. According to some embodiments of the present invention, the Coxsackievirus A16 (CA16) strain is deposited under CGMCC NO: 18886. According to some embodiments of the present invention, the Coxsackievirus A10 (CA10) strain is deposited under CGMCC NO: 18887. According to some embodiments of the present invention, the Coxsackievirus A6 (CA6) strain is deposited under CGMCC NO: 18888.
[0011] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated enterovirus 71 is 100-1000 U / mL, preferably 500-1000 U / mL.
[0012] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A16 is 200-3000 U / mL, preferably 200-1600 U / mL, and more preferably 800-1200 U / mL.
[0013] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A10 is 200-3000 U / mL, preferably 200-1600 U / mL, and more preferably 800-1200 U / mL.
[0014] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A6 group is 1000-3000 U / mL, preferably 1500-3000 U / mL, and more preferably 1600-2400 U / mL.
[0015] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A4 type is 200-3000 U / mL, preferably 1000-3000 U / mL, and more preferably 1600-2400 U / mL.
[0016] According to a specific embodiment of the present invention, the vaccine further includes an aluminum adjuvant. According to a specific embodiment of the present invention, the aluminum adjuvant is selected from aluminum hydroxide, aluminum phosphate, or aluminum sulfate. According to a specific embodiment of the present invention, the final concentration of aluminum content in the aluminum adjuvant, calculated as aluminum ions, is 0.1–1.0 mg / mL, preferably 0.2–0.8 mg / mL.
[0017] According to some embodiments of the present invention, the vaccine is a liquid dosage form.
[0018] According to another aspect of the present invention, a method for preparing the vaccine is also provided. According to some embodiments of the present invention, the method includes the following steps: preparing separate viral stock solutions, adsorbing the stock solutions onto aluminum adjuvants to prepare viral aluminum adsorption products, and then mixing the aluminum adsorption products to prepare the vaccine.
[0019] According to a specific embodiment of the present invention, a purified vaccine virus solution can be prepared by the following steps:
[0020] (1) Inactivate EV71, CA16, CA10, CA6 and CA4 viruses respectively, and concentrate them by ultrafiltration;
[0021] (2) The concentrated EV71, CA16, CA10, CA6 and CA4 virus solutions after ultrafiltration were subjected to sucrose density gradient centrifugation respectively.
[0022] (3) Collect the centrifuged liquid and combine it.
[0023] According to a specific embodiment of the present invention, viral purification solutions of EV71, CA16, CA10, CA6, and CA4 can be prepared in advance.
[0024] According to a specific embodiment of the present invention, EV71 stock solution can be prepared by the following steps: EV71 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a microcarrier fermenter for scale-up or in a cell factory for 5-9 days; the viral fluid is harvested; the viral fluid is inactivated by formaldehyde; ultrafiltration is performed using a 100-500 kDa ultrafiltration membrane for concentration; the ultrafiltration-concentrated viral fluid is purified by sucrose density gradient centrifugation; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease; host cell DNA is removed by ultrafiltration; and molecular sieve chromatography is used to remove impurities such as endonucleases to obtain EV71 virus stock solution.
[0025] According to a specific embodiment of the present invention, CA16 stock solution can be prepared by the following steps: CA16 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 4-9 days; the virus solution is harvested; the virus solution is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated virus solution is centrifuged using a sucrose density gradient to remove impurities; the collected target virus solutions are combined and desaccharified by ultrafiltration; the desaccharified virus solution is treated with a non-restriction endonuclease; host cell DNA is removed by ultrafiltration; molecular sieve chromatography is used to remove endonuclease and other impurities; and formaldehyde is used for inactivation to obtain CA16 virus stock solution.
[0026] According to a specific embodiment of the present invention, CA10 stock solution can be prepared by the following steps: CA10 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 2-9 days; the virus solution is harvested; the virus solution is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated virus solution is centrifuged using a sucrose density gradient to remove impurities; the collected target virus solutions are combined and desaccharified by ultrafiltration; the desaccharified virus solution is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove endonuclease and other impurities; and formaldehyde is used for inactivation to obtain CA10 virus stock solution.
[0027] According to a specific embodiment of the present invention, CA6 stock solution can be prepared by the following steps: CA6 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 3-9 days; the viral fluid is harvested; the viral fluid is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated viral fluid is centrifuged using a sucrose density gradient to remove impurities; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove endonuclease and other impurities; and formaldehyde is used for inactivation to obtain CA6 virus stock solution.
[0028] According to a specific embodiment of the present invention, CA4 stock solution can be prepared by the following steps: CA4 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 2-9 days; the viral fluid is harvested; the viral fluid is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated viral fluid is purified by sucrose density gradient centrifugation to remove impurities; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove residual endonucleases and other impurities; and formaldehyde is used for inactivation to obtain CA4 virus stock solution.
[0029] The virus purification process is carried out entirely using physical methods, which effectively removes impurities such as host proteins, host DNA, and endonucleases, thus ensuring vaccine safety.
[0030] The stock solutions of the five serotypes were adsorbed with aluminum adjuvants and then mixed in a certain proportion to prepare a vaccine semi-finished product, which was then packaged into a finished vaccine.
[0031] According to another aspect of the present invention, the use of the vaccine of the present invention in the prevention or treatment of hand-foot-mouth disease is provided.
[0032] The term "hand, foot, and mouth disease" or "HFMD" as used in this article refers to an acute infectious disease caused by various enteroviruses. Viruses that cause HFMD include enteroviruses (EVs) and Coxsackieviruses, with EV71 and CA16 being the most common. In addition, Coxsackieviruses include Coxsackievirus A (CA) types 2, 4, 5, 6, 10, and 24; Coxsackievirus B (CB) types 1, 2, 3, 4, and 5; enterovirus 68 (EV68); and echoviruses (Echo) types 6, 25, and 30.
[0033] According to a specific embodiment of the present invention, the vaccine can prevent or treat hand-foot-mouth disease caused by EV71, CA16, CA10, CA6, and / or CA4. In addition to hand-foot-mouth disease caused by the aforementioned viruses, the vaccine of the present invention can also prevent or treat hand-foot-mouth disease caused by other enteroviruses on a broader scale.
[0034] The term "cytopathic effect" or "CPE" used in this article refers to the phenomenon observed under a microscope in in vitro experiments after cell culture and inoculation with cell-killing viruses, characterized by cell rounding, necrosis, and detachment from the flask wall. Characteristic enterovirus-induced cytopathic effects typically manifest as cell rounding, increased refractive index, and detachment from the flask wall.
[0035] Currently, there are no reports on the development of pentavalent vaccines containing EV71, CA16, CA10, CA6, and CA4. This invention provides, for the first time, a pentavalent vaccine containing EV71, CA16, CA10, CA6, and CA4, which can effectively prevent hand-foot-and-mouth disease caused by EV71, CA16, CA10, CA6, and / or CA4 viruses. Studies have shown that the vaccine of this invention can simultaneously prevent infection by multiple pathogens, and there is no interference between these antigens. The corresponding immunogenicity is not reduced compared to the immunogenicity induced by a single antigen, exhibiting excellent immunogenicity and safety, good stability, and long-term storage. The use of multivalent vaccines can significantly simplify the vaccination procedure, improve vaccination efficiency, and reduce costs. The vaccine manufacturing process of this invention has good consistency and stability. Through extensive experiments, the optimal inactivation process parameters have been screened, which can improve the safety performance of the vaccine, achieve complete inactivation, and minimize the amount of formaldehyde used, saving costs. Detailed Implementation
[0036] The present invention will be further illustrated below by way of embodiments. It should be understood that these embodiments of the present invention are merely exemplary descriptions of the present invention and should not be construed as limiting the present invention.
[0037] Example 1. Isolation of the virus strain
[0038] Throat swabs or feces from patients with hand-foot-mouth disease were obtained from disease control and prevention centers in multiple locations. The samples were diluted with physiological saline, centrifuged, and filtered through 0.45μm and 0.22μm filters for sterilization. Sensitive cells (Vero cells or human diploid cells) with good cell growth and confluence into a monolayer were selected. The virus culture medium was M199 medium (GIBCO) containing 2% fetal bovine serum. The treated throat swabs / feces samples were inoculated at a specific ratio and incubated statically at 32.0℃–36.5℃ in a 5% CO2 incubator. The cells were observed daily for the presence of characteristic enterovirus-induced cytopathic effect (CPE). If CPE occurred and the CPE level reached +++ (1+, <25%; 2+, 25%–50%; 3+, 50%–75%; 4+, 75%–100%) or higher, the cell culture was harvested and passaged twice more. If no CPE occurs, culture until day 7, freeze-thaw once, harvest the cell culture, and passage the cell culture twice more. Use one well-grown cell culture tube that has not been inoculated as a cell control. If no CPE occurs in the cell control, the experiment is successful.
[0039] After three blind passages, the cell culture specimens showing CPE were judged to be positive for virus isolation, and the cell cultures that were positive for virus isolation were further identified by PCR.
[0040] Example 2. Identification of the strain
[0041] The strains isolated in Example 1 were identified at the immunological and molecular levels using ELISA and PCR, respectively.
[0042] (1) Identification by ELISA
[0043] EV71 antigen detection system: Coat with EV71 rabbit polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, add EV71 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, develop color, and terminate the reaction.
[0044] CA16 antigen detection system: Coat with CA16 rabbit polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash 3-5 times, add CA16 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash 3-5 times, develop color, and terminate the reaction.
[0045] CA10 antigen detection system: Coat with CA10 rabbit polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, add CA10 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, develop color, and terminate the reaction.
[0046] CA6 antigen detection system: Coat with CA6 polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash 3-5 times, add CA6 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash 3-5 times, develop color, and terminate the reaction.
[0047] CA4 antigen detection system: Coat with CA4 polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash 3-5 times, add CA4 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash 3-5 times, develop color, and terminate the reaction.
[0048] The five antigen detection systems described above were used to identify the strains isolated in Example 1, as well as the CA16, CA10, CA6, and EV71 strains used. The results are shown in Tables 1 to 5.
[0049] Table 1. Results of ELISA antigen identification of CA16 strain
[0050] Antigen detection system OD value Result judgment CA16 virus 2.010 Positive CA10 virus 0.044 Negative CA6 virus 0.067 Negative CA4 virus 0.051 Negative EV71 virus 0.049 Negative Negative control well 0.062 negative results
[0051] Table 2. Results of ELISA antigen identification of CA10 strain
[0052]
[0053]
[0054] Table 3. Results of ELISA antigen identification of CA6 strain
[0055] Antigen detection system OD value Result judgment CA16 virus 0.069 Negative CA10 virus 0.048 Negative CA6 virus 2.005 Positive CA4 virus 0.054 Negative EV71 virus 0.068 Negative Negative control well 0.051 negative results
[0056] Table 4. Results of ELISA antigen system identification of the strain isolated in Example 1
[0057] Antigen detection system OD value Result judgment CA16 virus 0.050 Negative CA10 virus 0.048 Negative CA6 virus 0.071 Negative CA4 virus 2.032 Positive EV71 virus 0.046 Negative Negative control well 0.060 negative results
[0058] Table 5. Results of ELISA antigen identification of EV71 strain
[0059] Antigen detection system OD value Result judgment CA16 virus 0.065 Negative CA10 virus 0.052 Negative CA6 virus 0.048 Negative CA4 virus 0.050 Negative EV71 virus 2.101 Positive Negative control well 0.059 Negative
[0060] (2) Identification at the molecular level
[0061] Viral RNA was extracted using an RNA extraction kit (QIAGEN), and the extracted RNA was subjected to one-step reverse transcription and PCR amplification using a reverse transcription kit (TAKARA). Primer sequences were designed in-house and synthesized by BGI Genomics Co., Ltd. The PCR products were identified by 1% agarose gel electrophoresis. Reverse transcription conditions:
[0062]
[0063] The virus was amplified by PCR and sequenced. The sequencing results were compared with the NCBI database, and the strain isolated in Example 1 was identified as Coxsackievirus A4 type virus strain. It was then sent to the China General Microbiological Culture Collection Center (CGMCC) for preservation, with the preservation number CGMCC NO:45051.
[0064] Example 3. Production of a single-component stock solution
[0065] The dosage of microcarriers (GE Healthcare, Cytodex) in a 130L fermenter is 2–6 g / L, based on a cell count of 10–50 × 10⁻⁶. 4 Inoculate Vero cells at a concentration of 10 cells / mL, pH 7.0–7.5, with dissolved oxygen fluctuating within a small range of approximately 50%. Culture at 35–37.5°C for 3–7 days. Based on the cell count, inoculate with virus at a ratio of 0.001–0.1 MOI and continue culturing for 3–6 days. Harvest the culture supernatant containing the virus.
[0066] The supernatant was clarified and concentrated using an ultrafiltration membrane of 100–500 kDa to remove impurities and proteins. The concentrated virus solution was then purified by sucrose density gradient centrifugation to remove impurities and separate hollow and solid virus particles. Centrifugation conditions were 2–8°C, 20,000–50,000 rpm, and 8–18 hours. The target viruses were collected and ultrafiltered for desaccharification. Non-restriction endonucleases were used to treat the desaccharified virus solution with stirring at 18–30°C. Then, host cell DNA was removed by ultrafiltration, and molecular sieve chromatography (GE Healthcare) was used to remove residual endonucleases and other impurities. The virus was then inactivated using a 1:2000–1:8000 formaldehyde solution at 35–38°C for 2–6 days until completely inactivated. These steps yielded inactivated stock solutions of CA6, CA16, CA10, and CA4 strains.
[0067] The production of EV71 stock solution is carried out by fermentation tanks or cell factory culture. After the virus is harvested, it is first inactivated and then purified. Other process steps are comparable to those of CA6, CA16, CA10 and CA4 strains.
[0068] Example 4. Preparation of monovalent aluminum adsorbed vaccine
[0069] Preparation of monovalent aluminum-adsorbed vaccines: Aluminum adjuvant was diluted to 3.0 mg / mL (calculated as Al(OH)3) with 0.85% physiological saline. EV71 antigen was diluted to 400-6000 U / mL with 0.01M PBS, CA16 and CA10 antigens were diluted to 800-9600 U / mL, CA6 antigen was diluted to 4000-18000 U / mL, and CA4 antigen was diluted to 3000-18000 U / mL. At room temperature, the diluted aluminum adjuvant was added to the diluted EV71, CA16, CA10, CA6, and CA4 antigens, respectively, so that the two were of equal volume for adsorption. Stirring was carried out while adding the adjuvant. After the adsorption was completed, the mixture was mixed at room temperature for 30 minutes to obtain monovalent aluminum-adsorbed vaccines of EV71, CA16, CA10, CA6, and CA4.
[0070] Example 5. Preparation of pentavalent vaccine
[0071] The five types of monovalent aluminum adsorption products mentioned above are mixed and packaged in a certain proportion to prepare a finished pentavalent hand-foot-mouth disease vaccine. The specific operation process is as follows:
[0072] The EV71, CA16, CA10, CA6, and CA4 monovalent aluminum adsorbed vaccines obtained above were mixed in a certain proportion. Based on the antigen content of the vaccine stock solution, they were appropriately diluted with 0.01M PBS (pH 7.2) solution and aluminum hydroxide solution. Then, the mixture was stirred and adsorbed at room temperature for 20±10 minutes to obtain the vaccine semi-finished product. In the obtained vaccine semi-finished product, the final concentration of aluminum hydroxide is approximately 1.30 mg / mL (equivalent to a final aluminum ion concentration of 0.45 mg / mL), the antigen content of EV71 is 960 U / mL, the antigen content of CA16 is 200–1600 U / mL, the antigen content of CA10 is 200–1600 U / mL, the antigen content of CA6 is 1000–3000 U / mL, and the antigen content of CA4 is 1000–3000 U / mL. The protein dose range corresponding to the above antigen contents in the semi-finished product is 1–8 μg / mL, that is, the total protein dose of the pentavalent semi-finished vaccine is 5–40 μg / mL. The obtained vaccine semi-finished product is then filled into syringes to obtain the finished vaccine. The dosage of the finished vaccine is 0.5 mL / person, and the protein content of each viral component in the finished vaccine is ≤4 μg / person.
[0073] The pentavalent hand-foot-mouth disease vaccine was prepared according to the above method, and the specific parameters are shown in Table 6. Three consecutive batches of vaccine were prepared for each parameter.
[0074] Table 6. Parameter settings for pentavalent combined vaccine
[0075]
[0076] Example 6. Evaluation of the pentavalent vaccine
[0077] (1) Testing of the finished pentavalent vaccine
[0078] The aluminum hydroxide content, supernatant antigen content, and post-dissociation antigen content of the pentavalent hand-foot-mouth disease vaccines 1-15 were detected respectively, and the adsorption rate and dissociation rate were calculated. The results are shown in Table 7.
[0079] Table 7. Test Results of the Finished Pentavalent Hand-Foot-Mouth Disease Vaccine
[0080]
[0081]
[0082] (2) Immunogenicity test
[0083] Three batches of pentavalent vaccine (Vaccine 1) were used to immunize rats and mice twice each, and the titers of neutralizing antibodies in their serum were detected. A monovalent vaccine control and a negative control were also established. The assay was repeated three times. Neutralizing antibody titers were detected using the microcytopathic effect method. Human malignant embryonic rhabdomyosarcoma (RD) cells were used for the assay; the cells were cultured at 37°C for 7 days, and cytopathic effects were observed. The results of neutralizing antibody titers and seroconversion rates are shown in Table 8. The immunogenicity of each viral component in the vaccine was statistically analyzed compared with the corresponding monovalent vaccine; the results are shown in Table 9. According to the statistical analysis, there was no significant difference in the GMT values of neutralizing antibodies between the pentavalent and monovalent vaccines (P values were all greater than 0.05).
[0084] Table 8. Neutralizing antibody titers and seroconversion rates
[0085]
[0086]
[0087] Table 9. Statistical analysis of the immunogenicity results of pentavalent and monovalent vaccines.
[0088]
[0089] (3) Safety evaluation
[0090] Throughout the experimental period assessing the immunogenicity of each vaccine, all animals survived healthily with no abnormal clinical manifestations. Abnormal toxicity tests were conducted on three batches of the EV71 / CA16 / CA10 / CA6 / CA4 pentavalent vaccine (Vaccine 1) to verify its animal safety evaluation.
[0091] The adverse toxicity tests included mouse and guinea pig studies. In the mouse study, five mice weighing 18–22g were injected with the EV71 / CA16 / CA10 / CA6 / CA4 pentavalent vaccine, 0.5 mL per mouse, and observed for 7 days. During the observation period, all mice survived without adverse reactions, and their body weight increased at the end of the observation period. In the guinea pig study, two guinea pigs weighing 250–350g were injected with the EV71 / CA16 / CA10 / CA6 / CA4 vaccine, 5 mL per guinea pig, and observed for 7 days. During the observation period, all guinea pigs survived without adverse reactions, and their body weight increased at the end of the observation period.
[0092] (4) Stability evaluation
[0093] Three batches of the combined vaccine (Vaccine 1) were stored at 2–8°C. Samples were taken at specific time points to test antigen content, appearance, dosage, pH value, osmolality, bacterial endotoxin, and formaldehyde content. Data were recorded for up to 12 months, and abnormal toxicity and immunogenicity of the vaccine were tested in December. After 12 months of storage at 2–8°C, no significant decrease was observed in any of the tested indicators. The results are shown in Tables 10–12.
[0094] Table 10. Antigen content test results of pentavalent vaccine finished product after storage at 2-8℃ for a period of time.
[0095]
[0096]
[0097] Table 11. pH value, osmolar concentration and sterility test of pentavalent vaccine finished product after storage at 2-8℃ for a period of time.
[0098]
[0099] Table 12. Toxicity and neutralizing antibody GMT of pentavalent vaccine finished product after storage at 2-8℃ for a period of time.
[0100]
[0101] Note: " / " indicates that this test was not performed.
[0102] In addition to vaccine 1, vaccines 2–15 also underwent immunogenicity testing, as well as safety and stability evaluations. The results showed that the neutralizing antibody GMT values of vaccines 2–15 were not significantly different from those of the monovalent vaccines. Furthermore, vaccines 2–15, like vaccine 1, exhibited good safety and high stability.
[0103] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details of the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solutions of the present invention, and these simple modifications all fall within the protection scope of the present invention. Furthermore, it should be noted that the various specific technical features described in the above embodiments can be combined in any suitable manner without contradiction. To avoid unnecessary repetition, the present invention will not describe the various possible combinations separately. In addition, various different embodiments of the present invention can also be arbitrarily combined, as long as they do not violate the spirit of the present invention, they should also be considered as the content disclosed by the present invention.
Claims
1. A vaccine for the prevention of hand-foot-mouth disease, characterized in that, The immunogen of the vaccine consists of inactivated Coxsackievirus A4, inactivated Enterovirus 71, inactivated Coxsackievirus A16, inactivated Coxsackievirus A10, and inactivated Coxsackievirus A6. The preservation number of the Coxsackievirus Group A4 strain is CGMCC NO: 45051; The preservation number of the enterovirus type 71 strain is CGMCC No. 3544; The preservation number of the Coxsackievirus Group A16 strain is CGMCC NO:18886; The preservation number of the Coxsackievirus Group A10 strain is CGMCC NO:18887; The preservation number of the Coxsackievirus Group A6 strain is CGMCC NO:18888.
2. The vaccine according to claim 1, characterized in that, In the vaccine, the content of the inactivated Coxsackievirus A4 is 200-3000 U / mL.
3. The vaccine according to claim 1, characterized in that, In the vaccine, the content of the inactivated Coxsackievirus A4 is 1000~3000 U / mL.
4. The vaccine according to claim 1, characterized in that, In the vaccine, The inactivated enterovirus 71 content is 100~1000 U / mL; The content of the inactivated Coxsackievirus A16 virus is 200~3000 U / mL; The content of the inactivated Coxsackievirus A10 virus is 200~3000 U / mL; The content of the inactivated Coxsackievirus A6 was 1000~3000 U / mL.
5. The vaccine according to claim 1, characterized in that, In the vaccine, the content of the inactivated enterovirus 71 is 500~1000 U / mL.
6. The vaccine according to claim 1, characterized in that, In the vaccine, the content of the inactivated Coxsackievirus A16 virus is 200~1600 U / mL.
7. The vaccine according to claim 1, characterized in that, In the vaccine, the content of the inactivated Coxsackievirus A10 virus is 200-1600 U / mL.
8. The vaccine according to claim 1, characterized in that, In the vaccine, the content of the inactivated Coxsackievirus A6 is 1500~3000 U / mL.
9. The vaccine according to any one of claims 1 to 8, characterized in that, The vaccine also includes an aluminum adjuvant.
10. The vaccine according to claim 9, characterized in that, The aluminum adjuvant is selected from aluminum hydroxide, aluminum phosphate, or aluminum sulfate.
11. The vaccine according to claim 9, characterized in that, The final concentration of aluminum in the aluminum adjuvant, calculated as aluminum ions, is 0.1~1.0 mg / mL.
12. The vaccine according to claim 9, characterized in that, The final concentration of aluminum in the aluminum adjuvant, calculated as aluminum ions, is 0.2~0.8 mg / mL.
13. A method for preparing a vaccine as described in any one of claims 1 to 12.
14. Use of the vaccine according to any one of claims 1 to 12 in the preparation of a medicament for the prevention of hand-foot-mouth disease.
Citation Information
Patent Citations
Combined vaccine for preventing hand-foot-and-mouth disease
CN106075423A
Viral particles as immunogens against enterovirus infection and production thereof
CN106661102A
Coxsackievirus CVA4 virus strain and application thereof
CN110452886A
Combined vaccine for preventing hand-foot-and-mouth disease as well as preparation method and application thereof
CN112717128A
Combined vaccine for preventing hand-foot-and-mouth disease as well as preparation method and application thereof
CN112791179A
